Braden Michael Leonard Sells 1,695,305 Shares of ProPhase Labs, Inc. (PRPH) Stock
ProPhase Labs, Inc. (NASDAQ:PRPH) major shareholder Braden Michael Leonard sold 1,695,305 shares of the company’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $2.30, for a total value of $3,899,201.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
ProPhase Labs, Inc. (NASDAQ PRPH) opened at 2.06 on Wednesday. ProPhase Labs, Inc. has a 12-month low of $1.78 and a 12-month high of $2.45. The stock’s 50 day moving average price is $2.23 and its 200-day moving average price is $2.08. The stock has a market capitalization of $33.30 million, a PE ratio of 0.86 and a beta of 0.02.
ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.09) earnings per share for the quarter. ProPhase Labs had a return on equity of 54.87% and a net margin of 270.98%. The business had revenue of $1.91 million for the quarter.
ProPhase Labs declared that its Board of Directors has authorized a stock repurchase program on Tuesday, August 15th that permits the company to repurchase 4,000,000 outstanding shares. This repurchase authorization permits the company to purchase shares of its stock through a tender offer. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.
About ProPhase Labs
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Stock Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related stocks with our FREE daily email newsletter.